NextCell

Interim Report Q3

JULY - SEPTEMBER 2026



● INTERIM REPORT

Quarter 3

"NextCell" or the "Company" refers to NextCell Pharma AB, corporate registration number 556965-8361. Amounts are stated in SEK unless otherwise indicated, and figures in brackets refer to the corresponding period in the previous year. Please note that, as of 2025, the Company's financial year corresponds to the calendar year.

Third quarter in brief

OPERATING INCOME, MSEK
2.8
(3.5)

NET INCOME, MSEK
2.7
(3.4)

PROFIT AFTER FINANCIAL ITEMS, MSEK
-7.5
(-6.8)

CASH AND CASH EQUIVALENTS, MSEK
13.9
(36.1)

TOTAL CASHFLOW, MSEK
-7.1
(-10.8)

EARNINGS PER SHARE*, SEK
-0.06
(-0.06)

EQUITY RATIO**
73%
(87 %)

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the third quarter of 2026: 126,392,959 (111,392,959) shares.
**Equity ratio: Shareholders' equity as a percentage of total assets.

INTERIM REPORT

Quarter 3

Significant events and news during the third quarter

- NextCell has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. At the same time, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026.

- NextCell presented its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell's clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

Significant events after the reporting period

- On 26th of October the 12-month result from ProTrans-Young was announced. In the predefined age group of 7–11 years, children treated with NXTCL-T1D had, on average, preserved a greater proportion of their endogenous insulin production after 12 months and experienced a smaller increase in insulin requirements compared with those receiving placebo. The study did not meet its primary efficacy endpoint in the overall study population. A preliminary analysis of 24-month data from the older age group shows no clear treatment effect, although the data have not yet been fully analysed or validated. NextCell's commercialisation strategy for adults remains unchanged, while the Company intends to refine its treatment strategy for children and adolescents, focusing on treatment timing and the number of administrations. Further analyses are also planned to investigate how age and individual disease progression may influence treatment response.

- The Company's Chief Scientific Officer, Dr Lindsay Davies, presented at BIO-Europe 2026 in Cologne, Germany. Her presentation addressed the challenges of taking allogeneic cell therapies from clinical development to commercial production.



● CEO COMMENT

NXTCL-T1D development remains focused on adult patients

Our strategy for NXTCL-T1D remains unchanged. We continue to focus on adults, who account for the largest share of type 1 diabetes diagnoses and in whom we have observed strong clinical results. At the same time, we are seeing interesting and consistently favourable numerical results in the youngest age group in ProTrans-Young.

Among children aged 7–11, we have seen encouraging results in terms of both preservation of insulin production and insulin requirements. However, at the one-year readout, the study did not meet its primary endpoint in the overall study population aged 7–21 years. One of the challenges is that the natural progression of the disease varies considerably between individuals, making it difficult to demonstrate a statistically significant treatment effect in a relatively small study. By comparison, the pivotal PROTECT trial of teplizumab enrolled 328 patients and recently led to FDA approval for the treatment of newly diagnosed children and adolescents with type 1 diabetes.

Our continued development is underpinned by the robust long-term data from our adult patients, where the difference between treated patients and placebo has been maintained over six years of follow-up. According to the International Diabetes Federation, adults also account for more than half of all new cases of type 1 diabetes. The true proportion may be even higher, as the condition is frequently misdiagnosed as type 2 diabetes in adults.

We are now progressing regional development programmes where local partnerships and regulatory pathways may offer a capital-efficient route to market. In parallel, we are working intensively to make NXTCL-T1D available through various "early access programmes". The very favourable safety profile observed in our clinical studies to date is an important foundation for these efforts, and I hope to be able to share further progress in the near future.

> "Our strategy for NXTCL-T1D remains unchanged. We continue to focus on adults, who account for the largest share of type 1 diabetes diagnoses and in whom we have observed strong clinical results."

Our subsidiaries also continue to make progress. Cellaviva is working to strengthen sales, develop its offering and streamline operations. This strengthens our position as the leading stem cell bank in the Nordic region and creates scope for improved margins. QVance is completing the final steps in setting up its laboratory and analytical services ahead of the start of commercial operations.



Securing the funding for the next stage of NextCell's development is our highest priority. We are actively pursuing several options to establish the financial foundation needed to advance our clinical results towards the market and make our treatment available to patients.

Thank you for your continued support,



Mathias Svahn, Ph.D.
CEO NextCell Pharma AB

ABOUT NEXTCELL

Vision, mission, strategy

NextCell Pharma is a clinical-stage cell therapy company developing and commercialize the proprietary NXTCL™-platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. The company was founded in 2014, and is headquartered in Huddinge next to the Karolinska University Hospital.

VISION

Standardising cell therapy for the treatment of inflammatory diseases

MISSION

Advancing the NXTCL stromal cell therapy platform, targeting inflammatory diseases with efficacious immunomodulation

STRATEGY

Provide scalable off-the-shelf cell therapy solutions increasing patient accessibility in the interventive treatments of immune-mediated disease

SHORT TERM

- Commercial execution of the TD1-program
- Cross jurisdictional scale-out of manufacturing capabilities
- Continuous process- and product development of the NXTCL-platform

LONG TERM

- Expansion of clinical pipeline
- Generate positive operating cash flow

ABOUT NEXTCELL

NXTCL™-platform

Next-generation MSC therapy designed for consistent potency and robust clinical effects.

Platform
- Proprietary donor selection enabling consistent potency
- Cryopreserved, ready-to-use therapy
- Scalable manufacturing with low variability

Clinical validation
- Demonstrated in randomized trial (Phase II)
- 100+ patients treated across 5 clinical trials
- Durable disease-modifying effect

Lead indication - Type 1 Diabetes
- Proof-of-concept in randomized trials
- Sustained preservation of endogenous insulin secretion

NXTCL™

NXTCL-T1D
LEAD INDICATION:
TYPE 1 DIABETES (PHASE II)

NXTCL-VRD
VIRAL RESPIRATORY DISEASES
(PHASE I & II*)

NXTCL-nRD
NEONATAL RESPIRATORY DISORDER
(PRECLINICAL)

NXTCL-CNS
THERAPEUTIC AREA (R&D):
CENTRAL NERVOUS SYSTEM

ABOUT NEXTCELL

NXTCL-T1D

A single infusion showed durable separation from placebo over 5 years.



5 years

PERSISTENT SEPARATION

~3-4x

GREATER PRESERVED INSULIN PRODUCTION AT YEAR 5

One treatment, multi-year biological effect

ABOUT NEXTCELL

Investments and strategic collaborations

NextCell has initiated and developed several companies based on capabilities and technologies originating from its cell therapy activities. These companies operate independently from NextCell's therapeutic development programs but remain strategically connected to the broader ecosystem around advanced cell therapies.

Cellaviva

Cellaviva is Scandinavia's largest private stem cell bank and offers services in stem cell preservation and advanced genetic testing. The company operates quality-assured laboratory processes for private individuals, companies, and partners requiring biological sample handling, storage, logistics, and genetic analysis services. NextCell owns 100% of the shares in Cellaviva AB.

QVance

QVance™ is a specialised provider of quality control services for cell and gene therapies as well as biological medicinal products. Whether you are an academic looking to transfer your ideas into GMP, or a company already in early or late-stage commercial development of a medicinal product, QVance provides consulting, quality program development, and services for quality control and batch release. NextCell owns 100% of the shares in QVance AB.

FamiCordTx Gene Therapies

FamiCordTx is a biotechnology company focused on developing cell and gene therapies for patients worldwide. One of its projects aims to create the world's first CAR-T cancer therapy ready for immediate administration, based on an allogeneic population bank. NextCell owns 8.5% of the shares in FamiCordTx.

FUJIFILM Biosciences Inc

NextCell and FUJIFILM Biosciences Inc has entered into a strategic collaboration to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardized MSC products, optimized culture media, and cryopreservation solutions.

Management



Mathias Svahn
CEO



Eric Gustafsson
CFO



Lindsay Davies
CSO/CEO QVance



Edvard Smith
CMO



Sofie Falk Jansson
CEO Cellaviva

Board of directors



Hans-Peter Ekre
Chairman of the board



Edvard Smith
Board member



Eva Sjökvist Saers
Board member



Camilla Myhre Sandberg
Board member

Advisory board

Angela Vollstedt

Per-Ola Carlsson

Eric Strati

● FINANCIAL REPORTS

Financial summary

Numbers in brackets in the report refer to the corresponding period in the previous year.
Please note that, as of 2025, the Company's financial year corresponds to the calendar year.

Operating Income

Net sales for the third quarter amounted to SEK 2.7 (3.4) million, of which Cellaviva accounted for SEK 2.6 (3.4) million. The change was primarily attributable to timing effects related to when customers enter into agreements and when invoicing for stem cell banking can take place. Other income for the third quarter amounted to SEK 0.1 (0.1) million.

Net sales for the first nine months amounted to SEK 8.4 (8.2) million, of which Cellaviva accounted for SEK 8.1 (7.5) million. Other income amounted to SEK 0.2 (0.2) million.

Result for the period

Profit after financial items for the third quarter amounted to SEK -7.5 (-6.8) million, while total operating expenses amounted to SEK -10.3 (-10.5) million, which is in line with last year but lower than in previous quarters, primarily due to reduced QVance establishment costs as the lab nears completion, as well as effective cost control.

Earnings per share for the third quarter amounted to SEK -0.06 (-0.06).

Profit after financial items for the first nine months amounted to SEK -29.6 (-25.6) million, while total operating expenses amounted to SEK -38.4 (-34.4) million, representing an increase of SEK 3.9 million and is attributable to the establishment of QVance's laboratory and analytical operations.

Earnings per share for the first nine months amounted to SEK -0.24 (-0.26).

Cash Position

NextCell's cash and cash equivalents as of September 30, 2026, amounted to SEK 13.9 (36.1) million. Total cash flow for the third quarter amounted to SEK -7.1 (-10.8) million, while cash flow from operating activities amounted to SEK -7.4 (-10.5) million.

Total cash flow for the first nine months of 2026 amounted to SEK -12.1 (3.4) million, while cash flow from operating activities amounted to SEK -26.8 (-27.0) million.

During the first quarter, a directed share issue was carried out to selected new specialist investors and existing shareholders to secure the Company's financing to achieve upcoming value driving milestones, as well as strategically broaden the shareholder base for the future. The Company raised SEK 15 million, and advisory costs had a marginal impact on the outcome.

Equity ratio

The Company's equity ratio as of September 30, 2026, was 73 (87) percent.

Contingent Liabilities

NextCell is engaged in an ongoing dispute with the supplier of the new production facility. While the outcome may lead to a limited financial obligation, it is expected to have a marginal impact overall.

Parent Company*

Operating income for the second quarter amounted to SEK 0.3 (0.2) million. Profit after financial items amounted to SEK -3.6 (-3.0) million. Cash and cash equivalents as of September 30, 2026, amounted to SEK 12.9 (34.3) million.

Operating income for the first nine months amounted to SEK 0.6 (0.5) million, while profit after financial items amounted to SEK -17.4 (-18.0) million.

* Cellaviva's Danish operations, conducted through a branch office and previously included in the parent company's income statement and balance sheet in the year-end report and annual report, are now reported under Cellaviva following adjustments to the legal structure during the first quarter.

● FINANCIAL REPORTS

Shares and Major Shareholders

The company's share is listed on First North Growth Market and is traded under the ticker "NXTCL". As of September 30, 2026, the number of shares amounted to 126,392,959 (111,392,959) and the share capital was 25,910,557 (22,835,557). The average number of shares during the third quarter amounted to 126,392,959 (111,392,959) and during the first nine months 121,887,464 (97,277,665).

All shares are of the same class and denominated in Swedish kronor (SEK). As of September 30, 2026, the number of shareholders amounted to approximately 4,800. The ten largest owners held shares corresponding to 40.8 percent of the total.

Below is the ten largest shareholders in NextCell as of 30 September, 2026

Name	No. of shares	Votes and capital (%)
Försäkringsaktiebolaget Avanza Pension	13,367,537	10.6 %
Bronsstädet AB	12,650,000	10.0 %
Nordnet Pensionsförsäkring AB	4,973,795	3.9 %
Ålandsbanken Abp (Finland), svensk filial	4,339,176	3.4 %
Diamyd Medical Aktiebolag	3,832,550	3.0 %
Hugo Stenbecks Stiftelse	3,000,000	2.4 %
Pabros AB	2,711,846	2.1 %
Staffan Ahlbom	2,530,000	2.0 %
1921 I EuVECA GmbH & Co	2,200,000	1.7 %
Filip Wirefors	2,000,000	1.6 %
Total 10 largest	**51,604,904**	**40.8 %**
Others	**74,788,055**	**59.2 %**
Total	**126,392,959**	**100.0 %**

FINANCIAL REPORTS

Income statement group

SEK	Q1-Q4 2025	Q3 2025	Q3 2026	Change %	Q1-Q3 2025	Q1-Q3 2026	Change %
Net income	9,957,654	3,384,622	2,662,142	-21 %	8,188,506	8,384,843	2 %
Other operating income	223,799	98,647	108,613	10 %	167,377	247,374	48 %
Total operating income	**10,181,453**	**3,483,269**	**2,770,755**	**-20 %**	**8,355,883**	**8,632,217**	**3 %**
Raw materials	-8,326,749	-1,776,079	-2,564,150	44 %	-6,398,932	-6,286,704	-2 %
Other external costs	-21,020,926	-4,264,343	-2,683,126	-37 %	-13,293,531	-14,768,230	11 %
Personnel costs	-18,388,199	-3,792,305	-4,446,209	17 %	-12,914,691	-15,450,152	20 %
Depreciation and amortisation	-2,494,322	-615,480	-616,935	0 %	-1,856,007	-1,859,114	0 %
Other operating expenses	89,014	-22,870	-	-100 %	42,969	-	-100 %
Total operating expenses	**-50,141,182**	**-10,471,079**	**-10,310,420**	**-2 %**	**-34,420,192**	**-38,364,200**	**11 %**
Operating profit/loss	**-39,959,729**	**-6,987,810**	**-7,539,665**	**8 %**	**-26,064,309**	**-29,731,983**	**14 %**
Interest income and similar income	611,052	168,667	18,008	-89 %	500,440	148,445	-70 %
Interest expenses and similar costs	-2,599	-964	-452	-53 %	-1,010	-1,833	81 %
Total financial items	**608,453**	**167,703**	**17,556**	**-90 %**	**499,430**	**146,612**	**-71 %**
Profit after financial items	**-39,351,276**	**-6,820,107**	**-7,522,109**	**10 %**	**-25,564,879**	**-29,585,371**	**16 %**
Tax expense for the period	-	-	-	-	-	-	-
Total result for the period	**-39,351,276**	**-6,820,107**	**-7,522,109**	**10 %**	**-25,564,879**	**-29,585,371**	**16 %**

● FINANCIAL REPORTS

Balance sheet group

SEK	31 Dec 2025	30 Sep 2025	30 Sep 2026
ASSETS			
Property, plant and equipment	14,267,511	14,120,765	12,898,507
Financial assets	8,253,476	8,008,454	8,271,888
Inventories	327,585	545,237	316,312
Trade receivables	3,061,688	3,001,011	3,669,233
Other short-term receivables	11,972,961	11,934,300	14,979,291
Cash and cash equivalents	26,033,645	36,115,620	13,943,063
Total assets	**63,916,867**	**73,725,387**	**54,078,293**
EQUITY AND LIABILITIES			
Share capital	*22,835,557*	*22,835,557*	*25,910,557*
Other contributed capital	*248,406,613*	*248,406,613*	*263,868,088*
Retained earnings, including net income for the year	*-220,643,666*	*-206,857,269*	*-250,229,036*
Total equity	50,598,504	64,384,901	39,549,608
Non-current non-interest-bearing liabilities	5,290,894	4,972,710	5,759,587
Trade payables	3,343,621	1,285,990	3,679,291
Other current liabilities	4,683,848	3,081,786	5,089,806
Total equity and liabilities	**63,916,867**	**73,725,387**	**54,078,293**

● FINANCIAL REPORTS

Changes in equity group

12 months	Share capital	Other contributed capital	Other equity inc. result for the period	Total equity
Opening balance 1 january 2025	**14,983,772**	**222,325,213**	**-181,292,390**	**56,016,595**
Changes in equity			0	0
New share issue	7,851,785	28,707,697		36,559,482
Share issue costs		-2,626,297		-2,626,297
Result for the period			-39,351,276	-39,351,276
Closing balance 31 december 2025	**22,835,557**	**248,406,613**	**-220,643,666**	**50,598,504**

9 months				
Opening balance 1 january 2025	**14,983,772**	**222,325,213**	**-181,292,390**	**56,016,595**
Issuance of warrants			0	0
New share issue	7,851,785	28,707,697		36,559,482
Share issue costs		-2,626,297		-2,626,297
Issuance of warrants				-
Result for the period			-25,564,879	-25,564,879
Closing balance 30 september 2025	**22,835,557**	**248,406,613**	**-206,857,269**	**64,384,901**

9 months				
Opening balance 1 january 2026	**22,835,557**	**248,406,613**	**-220,643,666**	**50,598,504**
Issuance of warrants			0	0
New share issue	3,075,000	11,925,000		15,000,000
Share issue costs		-238,525		-238,525
Issuance of warrants		3,775,000		3,775,000
Result for the period			-29,585,371	-29,585,371
Closing balance 30 september 2026	**25,910,557**	**263,868,088**	**-250,229,037**	**39,549,608**

● FINANCIAL REPORTS

Cash flow statement group

SEK	Q1-Q4 2025	Q3 2025	Q3 2026	Q1-Q3 2025	Q1-Q3 2026
Operating Activities					
Profit/loss before financial items	-39,959,729	-6,987,810	-7,539,665	-26,064,309	-29,731,983
Adjustments for non-cash items	3,102,775	783,183	634,492	2,355,437	2,005,726
Cash Flow from operating activities before changes in working capital	**-36,856,954**	**-6,204,627**	**-6,905,173**	**-23,708,872**	**-27,726,257**
Changes in working capital					
Increase/Decrease in operating receivables	-2,132,319	-280,975	2,048,637	-2,032,980	161,125
Increase/Decrease in operating liabilities	1,326,806	-426,341	-822,495	-275,256	405,958
Increase/Decrease in Inventories	217,652	-	11,273	-	11,276
Increase/Decrease in trade payables	1,123,610	-3,565,451	-1,751,148	-934,021	335,670
Total changes in working capital	**535,750**	**-4,272,767**	**-513,733**	**-3,242,257**	**914,029**
Cash Flow from operating activities	**-36,321,204**	**-10,477,394**	**-7,418,906**	**-26,951,129**	**-26,812,228**
Investing activities					
Investments in property, plant, and equipment	-4,848,699	-390,551	-	-4,063,637	-490,110
Investments in financial assets	-295,023	-	-	-50,000	-18,412
Cash Flow from investing activities	**-5,143,722**	**-390,551**	**-**	**-4,113,637**	**-508,522**
Financing activities					
Changes in long-term liabilities	869,019	351,802	273,469	550,835	468,693
New Share Issue	33,933,185	-283,877	-	33,933,185	14,761,474
Cash Flow from financing activities	**34,802,204**	**67,925**	**273,469**	**34,484,020**	**15,230,167**
Cash Flow for the period					
Cash and cash equivalents at the beginning of the period	32,696,366	46,915,639	21,088,500	32,696,366	26,033,645
Changes in cash and cash equivalents	-6,662,722	-10,800,020	-7,145,437	3,419,254	-12,090,583
Cash and cash equivalents at the end of the period	**26,033,645**	**36,115,620**	**13,943,063**	**36,115,620**	**13,943,062**

● FINANCIAL REPORTS

Income statement parent company

SEK	Q1-Q4 2025	Q3 2025	Q3 2026	Change %	Q1-Q3 2025	Q1-Q3 2026	Change %
Net income	7,513,351	0	251,414	-	231,114	435,344	88 %
Other operating income	216,749	177,941	23,845	-87 %	300,739	146,034	-51 %
Total operating income	**7,730,100**	**177,942**	**275,258**	**-**	**531,854**	**581,378**	**9 %**
Raw materials	-6,388,453	-	-320,682	-	-2,212,599	-870,941	-61 %
Other external costs	-15,325,191	-885,271	-610,380	-31 %	-7,976,723	-7,126,834	-11 %
Personnel costs	-10,710,085	-1,893,832	-2,437,745	29 %	-6,986,817	-8,376,849	20 %
Depreciation and amortisation	-2,458,028	-612,477	-589,506	-4 %	-1,847,141	-1,776,832	-4 %
Other operating expenses	-33,039	-4,934	52,464	-	-19,127	-	-100 %
Total operating expenses	**-34,914,798**	**-3,396,513**	**-3,905,850**	**15 %**	**-19,042,406**	**-18,151,455**	**-5 %**
Operating profit/loss	**-27,184,698**	**-3,218,572**	**-3,630,591**	**13 %**	**-18,510,553**	**-17,570,077**	**-5 %**
Interest income and similar income	663,876	181,657	17,772	-90 %	538,983	147,398	-73 %
Interest expenses and similar costs	-236	-117	-420	-	-163	-1,619	-
Total financial items	**663,640**	**181,540**	**17,352**	**-90 %**	**538,820**	**145,779**	**-73 %**
Profit after financial items	**-26,521,058**	**-3,037,031**	**-3,613,239**	**19 %**	**-17,971,732**	**-17,424,298**	**-3 %**
Tax expense for the period	-	-	-	-	-	-	-
Total result for the period	**-26,521,058**	**-3,037,031**	**-3,613,239**	**19 %**	**-17,971,732**	**-17,424,298**	**-3 %**

● FINANCIAL REPORTS

Balance sheet parent company

SEK	31 Dec 2025	30 Sep 2025	30 Sep 2026
ASSETS			
Property, plant and equipment	10,209,022	10,827,305	8,432,190
Financial assets	22,123,476	16,428,454	33,475,536
Inventories	327,585	545,237	316,312
Trade receivables	1,569,314	-	154,378
Intercompany receivables	16,558,086	18,341,325	38,321,254
Other short-term receivables	13,061,648	6,641,147	7,039,419
Cash and cash equivalents	25,489,570	34,259,392	12,873,088
Total assets	**89,338,701**	**87,042,860**	**100,612,175**
EQUITY AND LIABILITIES			
Share capital	*22,835,557*	*22,835,557*	*25,910,557*
Other contributed capital	*248,406,613*	*248,406,612*	*263,868,088*
Retained Earnings, Including Net Income for the Year	*-207,149,668*	*-195,740,037*	*-219,533,846*
Total equity	64,092,502	75,502,132	70,244,798
Non-current non-interest-bearing liabilities	1,592,782	-	-
Trade payables	2,647,155	1,422,567	2,476,589
Intercompany liabilities	18,020,333	8,350,000	25,150,000
Other current liabilities	2,985,929	1,768,161	2,740,787
Total equity and liabilities	**89,338,701**	**87,042,860**	**100,612,175**

Supplementary disclosures

General information and accounting principles

The interim report has been prepared in accordance with the Swedish Annual Accounts Act and BFNAR 2012:1 Annual Accounts and Consolidated Accounts ("K3"), as well as BFNAR 2007:1 ("Voluntary Interim Reporting"). For further information regarding accounting principles, please refer to NextCell's Annual Report for 2024/2025.

Risks

NextCells operations are associated with risks related to inter alia drug development, commercialization, financing, intellectual property, collaborations with partners, authority decisions, agreements and key personnel. For a description of the Company's risks, please see the Annual Report for the fiscal year 2024/2025. No significant changes in the Company's risk assessment have occurred since the Annual Report was issued.

Net sales by business segment

	Group		Parent company	
(SEK)	Q1-Q3 2026	Q1-Q3 2025	Q1-Q3 2026	Q1-Q3 2025
Stem Cell banking	8,088,433	7,546,548	0	0
Other	296,410	641,958	435,344	231,114
Total	**8,384,844**	**8,188,506**	**435,344**	**231,114**

Net sales by geographic market

	Group		Parent company	
(SEK)	Q1-Q3 2026	Q1-Q3 2025	Q1-Q3 2026	Q1-Q3 2025
Sweden	4,660,235	3,731,652	269,291	51,114
Denmark	3,428,199	3,814,896	0	30,000
Other	296,410	641,958	166,053	150,000
Total	**8,384,844**	**8,188,506**	**435,344**	**231,114**



● INFORMATION

Statement

The Board of Directors and the CEO certify that the interim report gives a fair overview of the business, position and profit or loss of the Company and describes the principal risks and uncertainties that face the Company.

Huddinge, November 26, 2026
NextCell Pharma AB (publ)

Hans-Peter Ekre
Chairman of the board

Edvard Smith
Board member

Eva Sjökvist Saers
Board member

Camilla Myhre Sandberg
Board member

Mathias Svahn
CEO

The Company's auditor have not reviewed the report for the third quarter of 2026.

Certified advisor

For companies listed on Nasdaq Firth North Growth Market, a Certified Adviser is required. NextCell has appointed Redeye Nordic Growth AB as Certified Adviser.

Calendar

Interim Report Q4 2026 2027-02-24
Interim Report Q1 2027 2027-05-27
Interim Report Q2 2027 2027-08-26
Interim Report Q3 2027 2027-11-25

Contacts

Financial reports are available on the Companys's website: www.nextcellpharma.com

For further information, please contact Mathias Svahn or Eric Gustafsson: info@nextcellpharma.com



WWW.NEXTCELLPHARMA.COM
HÄLSOVÄGEN 7, 141 57 HUDDINGE, SWEDEN